Guided Therapeutics to Report Q4 2011 Results and Hold Conference Call
March 14 2012 - 2:19PM
Business Wire
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer
of a rapid and painless testing platform that uses biophotonics for
the early detection of disease, today announced that it is
scheduled to report financial results for its fourth quarter and
year ended December 31, 2011 on Wednesday, March 28, 2012, after
the market closes.
Guided Therapeutics will hold a conference call at 11:00 a.m.
EDT Thursday, March 29, 2012, to discuss its financial results and
corporate developments. Interested parties are invited to listen to
the call live over the Internet at
http://www.guidedinc.com/investors.htm or http://www.viavid.net.
The live call is also available by dialing (877) 397-0292 or for
international callers (719) 325-4921.
A replay of the teleconference will be available on
http://www.guidedinc.com/investors.htm. A replay will also be
available until April 4, 2012 by dialing (877) 870-5176 or (858)
384-5517, and using pin number 3941500.
About Guided Therapeutics
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is
developing a rapid and painless testing platform for the early
detection of disease based on its patented biophotonic technology
that utilizes light to detect disease at the cellular level. The
company’s first planned product is the LuViva® Advanced Cervical
Scan, a non-invasive device used to detect cervical disease
instantly and at the point of care. In a multi-center clinical
trial, with women at risk for cervical disease, the technology was
able to detect cervical cancer up to two years earlier than
conventional modalities, according to published reports. Guided
Therapeutics has also entered into a partnership with Konica
Minolta Opto to develop a non-invasive test for Barrett’s Esophagus
using the technology platform. For more information, visit:
www.guidedinc.com.
The Guided Therapeutics LuViva® Advanced Cervical Scan is an
investigational device and is limited by federal law to
investigational use.
LuViva, the wave logo and "Early detection, better outcomes" are
registered trademarks owned by Guided Therapeutics, Inc.
Forward-Looking Statements Disclaimer: A number of the matters
and subject areas discussed in this news release that are not
historical or current facts deal with potential future
circumstances and developments. The discussion of such matters and
subject areas is qualified by the inherent risks and uncertainties
surrounding future expectations generally and also may materially
differ from Guided Therapeutics’ actual future experience involving
any of or more of such matters and subject areas. Such risks and
uncertainties include: the early stage of products in development,
the uncertainty of market acceptance of products, the uncertainty
of development or effectiveness of distribution channels, the
intense competition in the medical device industry, the uncertainty
of capital to develop products, the uncertainty of regulatory
approval of products, dependence on licensed intellectual property,
as well as those that are more fully described from time to time
under the heading “Risk Factors” in Guided Therapeutics’ reports
filed with the SEC, including Guided Therapeutics’ Annual Report on
Form 10-K for the fiscal year ended December 31, 2010, and
subsequent quarterly reports.
Guided Therapeutics (QB) (USOTC:GTHP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guided Therapeutics (QB) (USOTC:GTHP)
Historical Stock Chart
From Sep 2023 to Sep 2024